AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 81 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2022. The put-call ratio across all filers is 1.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $42,193,208 | -33.1% | 4,096,428 | +7.0% | 4.62% | +6.1% |
Q2 2023 | $63,111,429 | +83.2% | 3,829,577 | +1.8% | 4.36% | +82.2% |
Q1 2023 | $34,454,772 | +174628.8% | 3,761,438 | +36.6% | 2.39% | +5.3% |
Q4 2022 | $19,719 | -99.9% | 2,754,095 | -6.2% | 2.27% | +39.7% |
Q3 2022 | $14,715,000 | +105.3% | 2,937,093 | 0.0% | 1.62% | +125.7% |
Q2 2022 | $7,167,000 | -64.3% | 2,937,093 | 0.0% | 0.72% | -47.9% |
Q1 2022 | $20,060,000 | -15.5% | 2,937,093 | 0.0% | 1.38% | -3.5% |
Q4 2021 | $23,732,000 | -17.6% | 2,937,093 | 0.0% | 1.43% | +10.8% |
Q3 2021 | $28,784,000 | +45.6% | 2,937,093 | 0.0% | 1.29% | +50.9% |
Q2 2021 | $19,767,000 | -25.6% | 2,937,093 | 0.0% | 0.86% | -8.3% |
Q1 2021 | $26,551,000 | +12.7% | 2,937,093 | -16.7% | 0.93% | -11.2% |
Q4 2020 | $23,554,000 | +32.5% | 3,526,093 | 0.0% | 1.05% | +2.3% |
Q3 2020 | $17,772,000 | -37.6% | 3,526,093 | 0.0% | 1.03% | -49.7% |
Q2 2020 | $28,491,000 | +0.4% | 3,526,093 | -1.4% | 2.04% | -20.6% |
Q1 2020 | $28,389,000 | – | 3,575,424 | – | 2.57% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |